Picture of Arcturus Therapeutics Holdings logo

ARCT — Arcturus Therapeutics Holdings News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Arcturus Therapeutics Holdings Inc reports results for the quarter ended June 30 - Earnings Summary

Arcturus Therapeutics Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
  • Arcturus Therapeutics Holdings Inc ARCT.OQ reported a quarterly adjusted loss of 84 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -34 cents. The mean expectation of twelve analysts for the quarter was for a loss of 100 cents per share. Wall Street expected results to range from $-1.35 to -74 cents per share.

  • Revenue fell 89.5% to $2.96 million from a year ago; analysts expected $3.20 million.

  • Arcturus Therapeutics Holdings Inc's reported EPS for the quarter was a loss of 84 cents​.

  • The company reported a quarterly loss of $23.79 million.

  • Arcturus Therapeutics Holdings Inc shares had fallen by 6.8% this quarter and gained 2.1% so far this year.

FORECAST CHANGES

  • The mean earnings estimate of analysts had risen by about 7.3% in the last three months.​

  • In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

  • Wall Street's median 12-month price target for Arcturus Therapeutics Holdings Inc is $20.00, about 68.7% above its last closing price of $6.26

This summary was machine generated from LSEG data August 6 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING

ESTIMATE

ACTUAL

BEAT, MET, MISSED

Jun. 30 2026

-1.00

-0.84

Beat

Mar. 31 2026

-1.09

-0.95

Beat

Dec. 31 2025

-0.71

-1.03

Missed

Sep. 30 2025

-0.82

-0.49

Beat

Recent news on Arcturus Therapeutics Holdings

See all news